RxDoctor Payments Data

Jennifer Rice

Primary Care · Boise, IDNPI 1538631189

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $142 of the $177 with a category attached, or 80.3%. It is spread thinly across 9 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $126 and has fallen 86.9% since, to $16 in 2025. That places this record below the midpoint for primary care clinicians in ID, where the typical reported total is $390.

$177in general payments, 2019–2025

Across 10 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$35
  • AstraZeneca$27
  • Dexcom, Inc.$20
  • Novartis$17
  • Mylan Specialty L.p.$17
  • AbbVie$16
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$14280%
  • Education$3520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$177 in reported general payments places this provider in the 30th percentile of 48 primary care providers in Idaho.

See all primary care providers in Idaho

Medicare billing

Part B allowed, 2024
$823
Medicare patients
83
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,837
Novolog FlexpenInsulin Aspart11$2,964
Montelukast Sodium15$403
Pantoprazole Sodium25$367
Rosuvastatin Calcium27$358
Lisinopril16$327
Diclofenac Sodium15$299
Albuterol Sulfate HfaAlbuterol Sulfate17$291
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$273
Cephalexin44$252
Metoprolol Succinate19$245
Tamsulosin Hcl12$186
Azithromycin50$180
Atorvastatin Calcium18$179
Metronidazole14$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$27$6,83711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 48 primary care providers in Idaho.

Other primary care in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →